Reddy Bollu
A5051902663- Radiopharmaceutical Chemistry and Applications
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Nanoparticle-Based Drug Delivery
Mersana Therapeutics (United States)
2016-2023
Antibody-drug conjugates (ADC) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many types. The activity safety profile of an ADC depends on its construction: antibody, payload, linker, conjugation method, as well the number payload drugs per antibody [drug-to-antibody ratio (DAR)]. To allow for optimization given target antigen, we developed Dolasynthen (DS), novel platform based auristatin hydroxypropylamide, that enables precise DAR-ranging site-specific...
Abstract The type II sodium-dependent potassium transporter NaPi2b (SLC34A2) is highly expressed in non-squamous NSCLC and non-mucinous ovarian cancer (OC) with restricted normal tissue expression, suggesting it may be a suitable ADC target for these indications. XMT-1536 novel, potent anti-NaPi2b comprised of an average 15 auristatin molecules conjugated to XMT-1535, novel humanized antibody, via the Dolaflexin platform. payload enzymatically cleaved upon trafficking endosome/lysosome...
<p>Supplementary Materials</p>
<div>Abstract<p>Antibody-drug conjugates (ADCs) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many types. The activity safety profile of an ADC depends on its construction: antibody, payload, linker, conjugation method, as well the number payload drugs per antibody (drug-to-antibody ratio, DAR). To allow for optimization given target antigen, we developed Dolasynthen, novel platform based auristatin hydroxypropylamide (AF-HPA), that enables...
<p>Supplementary Materials</p>
<div>Abstract<p>Antibody-drug conjugates (ADCs) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many types. The activity safety profile of an ADC depends on its construction: antibody, payload, linker, conjugation method, as well the number payload drugs per antibody (drug-to-antibody ratio, DAR). To allow for optimization given target antigen, we developed Dolasynthen, novel platform based auristatin hydroxypropylamide (AF-HPA), that enables...
<p>Supplementary Materials</p>
<p>Supplementary Materials</p>
<div>Abstract<p>Antibody–drug conjugates (ADC) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many types. The activity safety profile of an ADC depends on its construction: antibody, payload, linker, conjugation method, as well the number payload drugs per antibody [drug-to-antibody ratio (DAR)]. To allow for optimization given target antigen, we developed Dolasynthen (DS), novel platform based auristatin hydroxypropylamide, that enables...